Τίτλος:
MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
MicroRNA-155-5p (miR-155-5p) is a proinflammatory, oncogenic miRNA, involved in various physiological processes, including hematopoiesis, immunity, inflammation, and cell lineage differentiation. It regulates important transcription factors, such as E2F2, hypoxia-inducible factor 1 (HIF1), and FOXO3. Recently, the dysregulation of miR-155-5p expression has been linked to chronic lymphocytic leukemia (CLL) pathogenesis. In this research study, we investigated the potential diagnostic and prognostic value of miR-155-5p in CLL. To achieve our goal, we isolated total RNA from peripheral blood mononuclear cells (PBMCs) collected from 88 CLL patients and 36 nonleukemic blood donors and performed polyadenylation of total RNA and reverse transcription. Next, we quantified miR-155-5p levels using an in-house-developed real-time quantitative PCR method, before proceeding to extensive biostatistical analysis. Thus, it appears that miR-155-5p is significantly overexpressed in PBMCs of CLL patients and can distinguish them from nonleukemic population. Kaplan-Meier OS analysis and bootstrap univariate Cox regression showed that high miR-155-5p expression predicts inferior OS for CLL patients (p<0.001). Interestingly, miR-155-5p overexpression retains its unfavorable prognostic role in CLL patients stratified according to established prognostic factors [CD38 expression and mutational status of the immunoglobulin heavy chain variable region (IGHV)]. Thus, miR-155-5p appears as a promising, independent molecular biomarker of unfavorable prognosis in CLL. © 2017 Sotirios G. Papageorgiou et al.
Συγγραφείς:
Papageorgiou, S.G.
Kontos, C.K.
Diamantopoulos, M.A.
Bouchla, A.
Glezou, E.
Bazani, E.
Pappa, V.
Scorilas, A.
Περιοδικό:
Disease Markers
Λέξεις-κλειδιά:
immunoglobulin heavy chain; microRNA; microRNA 155 5p; unclassified drug; microRNA; MIRN155 microRNA, human; tumor marker, adult; aged; Article; B cell leukemia; blood donor; cancer diagnosis; cancer patient; cancer prognosis; chronic lymphatic leukemia; controlled study; cost effectiveness analysis; female; gene overexpression; green chemistry; human; human cell; major clinical study; male; peripheral blood mononuclear cell; polyadenylation; real time polymerase chain reaction; reverse transcription; blood; chronic lymphatic leukemia; gene expression regulation; genetics; middle aged; prognosis; survival analysis; tumor cell line; upregulation; very elderly, Aged; Aged, 80 and over; Biomarkers, Tumor; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MicroRNAs; Middle Aged; Prognosis; Survival Analysis; Up-Regulation
DOI:
10.1155/2017/2046545
